RxDoctor Payments Data

Kiran Patil, MD

Neurology · Bethel Park, PANPI 1538585880

Payments from drug & device makers

$7,540in general payments, 2019–2025

Across 373 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$924
  • Teva Pharmaceuticals USA, Inc.$522
  • Novartis$485
  • Eisai Inc.$469
  • EMD Serono, Inc.$329
  • plus $4K from 39 others

What the payments were for

  • Speaking & faculty fees$1192%
  • Travel & lodging$70%
  • Food & beverage$7,32097%
  • Education$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,540 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$35,073
Medicare patients
145
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$154,949
AmpyraDalfampridine12$51,492
NeurontinGabapentin12$21,882
BriviactBrivaracetam11$15,444
QuliptaAtogepant11$11,980
Nurtec OdtRimegepant Sulfate12$11,510
Levetiracetam158$3,984
Memantine Hcl202$3,429
Carbamazepine ErCarbamazepine12$2,228
Carbidopa-LevodopaCarbidopa/Levodopa107$2,115
Lacosamide18$2,051
Pyridostigmine Bromide36$1,880
Lamotrigine131$1,722
Mycophenolate Mofetil12$1,503
Gabapentin187$1,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$78$154,94911 claims
Acorda Therapeutics, IncAmpyra$261$51,49212 claims
UCB, Inc.Briviact$924$15,44411 claims
AbbVieQulipta$1,189$11,98011 claims
PfizerNurtec Odt$37$11,51012 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$104$3,38348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Bethel Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →